Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

Z Yuan, Y Li, S Zhang, X Wang, H Dou, X Yu, Z Zhang… - Molecular cancer, 2023 - Springer
The malignant tumor is a multi-etiological, systemic and complex disease characterized by
uncontrolled cell proliferation and distant metastasis. Anticancer treatments including …

[HTML][HTML] Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents

M Hashemi, MSA Mirdamadi, Y Talebi… - Pharmacological …, 2023 - Elsevier
The field of non-coding RNA (ncRNA) has made significant progress in understanding the
pathogenesis of diseases and has broadened our knowledge towards their targeting …

Cytokines: can cancer get the message?

RM Morris, TO Mortimer, KL O'Neill - Cancers, 2022 - mdpi.com
Simple Summary Cytokines are important molecular players in cancer development,
progression, and potential targets for treatment. Despite being small and overlooked …

Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013–2023)

S Almutairi, HM Kalloush, NA Manoon, SK Bardaweel - Molecules, 2023 - mdpi.com
Matrix metalloproteinases (MMPs) are identifiable members of proteolytic enzymes that can
degrade a wide range of proteins in the extracellular matrix (ECM). MMPs can be …

Matrix metalloproteinase 2 as a pharmacological target in heart failure

PR Gonçalves, LD Nascimento, RF Gerlach… - Pharmaceuticals, 2022 - mdpi.com
Heart failure (HF) is an acute or chronic clinical syndrome that results in a decrease in
cardiac output and an increase in intracardiac pressure at rest or upon exertion. The …

[HTML][HTML] Screening a panel of topical ophthalmic medications against MMP-2 and MMP-9 to investigate their potential in keratoconus management

A Belal, MA Elanany, EY Santali, AA Al-Karmalawy… - Molecules, 2022 - mdpi.com
Keratoconus (KC) is a serious disease that can affect people of any race or nationality,
although the exact etiology and pathogenic mechanism are still unknown. In this study, thirty …

Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) …

SA Amin, S Khatun, S Gayen, S Das, T Jha - European Journal of Medicinal …, 2023 - Elsevier
Abstract Histone deacetylase 8 (HDAC8) aberrantly deacetylates histone and non-histone
proteins. These include structural maintenance of chromosome 3 (SMC3) cohesin protein …

Selective inhibitors of medium-size S1′ pocket matrix metalloproteinases: a stepping stone of future drug discovery

SK Baidya, S Banerjee, N Adhikari… - Journal of Medicinal …, 2022 - ACS Publications
Among various matrix metalloproteinases (MMPs), MMPs having medium-size S1′ pockets
are established as promising biomolecular targets for executing crucial roles in cancer …

Recent progress in nanocarrier-based drug delivery systems for antitumour metastasis

S Peng, X Yuan, H Li, Y Wei, B Zhou, G Ding… - European Journal of …, 2023 - Elsevier
Tumour metastasis is one of the major factors leading to poor prognosis as well as lower
survival among cancer patients. A number of studies investigating the inhibition of tumour …

Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics

T Akinsipe, R Mohamedelhassan, A Akinpelu… - Frontiers in …, 2024 - frontiersin.org
The breast cancer tumor microenvironment (TME) is dynamic, with various immune and non-
immune cells interacting to regulate tumor progression and anti-tumor immunity. It is now …